BrandywineGLOBAL – Global Income Opportunities Fund Inc. ("BWG") Clarion Partners Real Estate Income Fund Inc. ("CPREIF") ClearBridge Energy Midstream Opportunity Fund Inc. ("EMO") LMP Capital and Income Fund Inc. ("SCD") Western Asset Diversified Income Fund ("WDI") Western Asset Emerging Markets Debt Fund Inc. ("EMD") Western Asset Global Corporate Opportunity Fund Inc. ("GDO") Western Asset Global High Income Fund Inc. ("EHI") Western Asset High Income Fund II Inc. ("HIX") Western Asset High Income Opportunity Fund Inc. ("HIO") Western Asset High Yield Defined Opportunity Fund Inc. ("HYI") Western Asset Intermediate Muni Fund Inc. ("SBI") Western Asset Investment

Business Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol "ALVO" from June 16, 2022 on The Nasdaq Stock Market in New York and from June 23, 2022 on the Nasdaq First North Growth Market in Iceland Warrants expected to trade on The Nasdaq Stock Market in New York under the new ticker symbol "ALVOW"  Alvotech Holdings S.A. ("Alvotech S.A."), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II ("OACB") (NYSE:OACB), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Man

Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp. II (NYSE:OACB) ("OACB" or the "Company") announced today that, assuming satisfaction of the conditions to the closing of its pending business combination with Alvotech Holdings S.A. and Alvotech ("Topco") (the "Business Combination"), including approval of the Business Combination by the Company's shareholders, Topco, as the surviving entity, intends to list its ordinary shares on The Nasdaq Stock Market LLC and the Nasdaq First North Growth Market (together "Nasdaq") under the new ticker symbol "ALVO" and its warrants on The Nasdaq Stock Market LLC

The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech's biosimilars and biosimilar candidates, which includes AVT02 (adalimumab), a biosimilar to Humira® Alvotech is the second company to announce positive top-line results from a patient study utilizing a biosimilar candidate to Stelara® Alvotech Holdings S.A. ("Alvotech"), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive results from a confirmatory clinical study for AVT04, Alvotech's proposed

- Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product Stelara® Alvotech Holdings S.A. ("Alvotech"), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a pharmacokinetic (PK) study for AVT04, Alvotech's proposed biosimilar to Stelara® (ustekinumab). The PK similarity study (AVT04-GL-101) utilized a single dose, 3-arm, parallel design to compare pharmacokinetics, safety, tolerability, and immunogenicity of a single 45mg/0.5mL subcutaneous dose of AVT04, with US-licensed Stelara®, as well as EU-approve

Alvotech Holdings S.A. ("Alvotech S.A."), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE:OACB), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. ("OACB"), announced today that the extraordinary general meeting of shareholders of OACB (the "Extraordinary General Meeting") to approve the pending business combination (the "Business Combination") between Alvotech S.A., Alvotech ("TopCo") and OACB is scheduled to be held on Tuesday, June 7, 2022 at 10:00 a.m. Eastern time. The Extraordinary General Meeting will be held in

Alvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company's capital position and to replace any redeemed capital as part of their proposed merger Parties agree to reduce the minimum cash condition outlined in the merger agreement, thereby enhancing deal certainty in their proposed business combination Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that, subject to the completion of the announced business combination (the "Business Combination") between Alvotech, Alvotech Lux Holdings S.A.S. ("the Company") and Oakt

 Upon launch, HUKYNDRA® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market All intellectual-property disputes related to market entry of Alvotech's AVT02 (adalimumab) in the U.S. and Europe are now resolved Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, has today announced the resolution of all intellectual property disputes with AbbVie in Europe and selected markets outside of Europe, related to its AVT02 biosimilar candidate. This paves the way for Alvotech's exclusive strategic partner STADA to commercialize AVT02,

Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023 All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought forth in December 2021 Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that is has executed a U.S. settlement agreement with AbbVie (NYSE:ABBV) that grants Alvotech non-exclusive rights to market AVT02 (100mg/mL), its high-concentration, citrate-free biosimilar candidate for Humira® (adalimumab) in the United States. The settlement gran

Alvotech is the only known company to have both developed a high-concentration biosimilar to Humira and conducted a switching study to support interchangeability Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's Biologics Licensing Application (BLA) for ATV02 (100 mg/mL) that includes new data supporting interchangeability between ATV02 and Humira. The data are from a randomized study (AVT02-GL-302; NCT04453137) in patients that demonstrate bioequivalence of repeated swi

25 - Oaktree Acquisition Corp. II (0001820931) (Filer)

8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)

8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)

8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)

8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)

10-Q - Oaktree Acquisition Corp. II (0001820931) (Filer)

DEFM14A - Oaktree Acquisition Corp. II (0001820931) (Filer)

8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)

8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)

8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)

BrandywineGLOBAL – Global Income Opportunities Fund Inc. ("BWG") Clarion Partners Real Estate Income Fund Inc. ("CPREIF") ClearBridge Energy Midstream Opportunity Fund Inc. ("EMO") LMP Capital and Income Fund Inc. ("SCD") Western Asset Diversified Income Fund ("WDI") Western Asset Emerging Markets Debt Fund Inc. ("EMD") Western Asset Global Corporate Opportunity Fund Inc. ("GDO") Western Asset Global High Income Fund Inc. ("EHI") Western Asset High Income Fund II Inc. ("HIX") Western Asset High Income Opportunity Fund Inc. ("HIO") Western Asset High Yield Defined Opportunity Fund Inc. ("HYI") Western Asset Intermediate Muni Fund Inc. ("SBI") Western Asset Investment

Northland Capital initiated coverage of Oaktree Acquisition Corp. II with a rating of Outperform and set a new price target of $15.00

3/A - Oaktree Acquisition Corp. II (0001820931) (Issuer)

SC 13G - Oaktree Acquisition Corp. II (0001820931) (Subject)

SC 13G/A - Oaktree Acquisition Corp. II (0001820931) (Subject)

SC 13G - Oaktree Acquisition Corp. II (0001820931) (Subject)